174, av. de France
189 articles about Sanofi Pasteur
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
Sanofi Pasteur and Translate Bio have partnered to develop a novel messenger RNA vaccine for COVID-19, the disease caused by the novel coronavirus.
To date, there are more than 72,000 confirmed and suspected cases of COVID-19 and 1,023 deaths from COVID-19, most in mainland China.
The site location is in Swiftwater, Pennsylvania.
FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas
The U.S. Food and Drug Administration approved Dengvaxia® for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection.
Here’s a look at this week’s calendar for decisions coming down from the U.S. Food and Drug Administration (FDA).
BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance
BERG today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader.
Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca PLC's MedImmune
Sanofi Pasteur Announces The Availability of Quadracel DTaP-IPV Vaccine For Children 4 Through 6 Years Of Age In The U.S.
Sanofi Pasteur and Merck & Co. Terminate Joint Vaccines Biz in Europe, Effective Immediately
Sanofi Pasteur Abandons Bladder Cancer Drug
Sanofi Pasteur Release: High-Dose Influenza Vaccine With Evidence Of Superior Efficacy* In Older Adults: Now In Canada
Sanofi Pasteur Nabs $43 Million U.S. Funding to Speed Up Zika Vaccine Development
Dyadic Stock Tanks Amid Reports of Partnership Termination With Sanofi Pasteur
Sanofi Pasteur Ships First Of Its 2016-2017 Seasonal Influenza Vaccine Doses In United States
New Four-Strain Influenza Vaccine, VaxigripTetra, Regulatory Dossier From Sanofi Pasteur Now Approved In Europe
Terrapinn Release: Experts From Merck & Co., GlaxoSmithKline, Pfizer, Sanofi Pasteur And More To Debate Breakthroughs For Vaccines For Ebola, Zika And Cancer.